Category: Abiomed Inc.
Abiomed says it acquired German heart pump maker ECP Entwicklungsgesellschaft in a deal worth up to $30 million, including milestones.
Abiomed (NSDQ:ABMD) said yesterday that it acquired a German heart pump maker in a deal worth up to $30 million.
Here's a look at some of the top legal news stories for medical device companies this week: Appeals court upholds Gore win over St. Jude Medical; Independent legal panel rejects Infuse allegations in Medtronic shareholder suits; Judge dismisses Anulex from Xclose off-label lawsuit; Appeals court upholds Abiomed win in shareholder's class action; Convicted ex-Heart Tronics CEO won't get a retrial, judge rules.
A federal appeals court upholds a lower court's decision to dismiss a shareholder derivative lawsuit accusing Abiomed and its management of artificially inflating its stock price by concealing allegedly improper marketing of its Impella 2.5 heart pump.
Abiomed (NSDQ:ABMD) held on to its win in a shareholder's lawsuit filed against it in 2013 when a federal appeals court yesterday upheld a lower court's decision to dismiss the case.
The MedTech and BioTech Veterans Program will host its 1st Student Veteran Re-careering Seminar in Boston later this month.
MASSDEVICE ON CALL — Device makers are joining forces with Massachusetts' higher education to help military veterans get their foot in the door with a career in medtech.
Abiomed says the FDA approved its bid to expand the Recover Right trial of its Impella RP heart pump.
Abiomed (NSDQ:ABMD) said the FDA will allow it to nearly double enrollment in a clinical trial of its Impella RP right-side heart pump, the Recover Right study, as it seeks a humanitarian device exemption from the watchdog agency.
Abiomed says the U.S. Health & Human Services Dept. is investigating payments it made to healthcare providers.
Abiomed (NSDQ:ABMD) today revealed a federal probe into payments it made to healthcare providers in 2012.
Abiomed says it's renewing a licensing deal with Opsens for fiber-optic pressure sensor technology to integrate into its Impella line of heart pumps.
Abiomed (NSDQ:ABMD) said it renewed a licensing deal with Opsens (TSX:OPS.V) to integrate that company's fiber-optic pressure sensor technology into Abiomed's Impella line of heart pumps.